Bausch + Lomb Advances Two Eye Therapies With Blockbuster Sales Potential
Bausch + Lomb (NYSE: BLCO) advances two first-in-class eye drugs to advanced clinical testing, eyeing $2B+ in peak sales.
Bausch + Lomb is testing two new eye medicines that could become really popular and make lots of money. When a company moves forward with promising drugs, it shows investors the company might grow, so watch how the stock reacts over time.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.